OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited
- PMID: 15094138
- DOI: 10.1016/j.joca.2004.02.001
OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited
Abstract
Background: The OARSI Standing Committee for Clinical Trials Response Criteria Initiative had developed two sets of responder criteria to present the results of changes after treatment in three symptomatic domains (pain, function, and patient's global assessment) as a single variable for clinical trials (1). For each domain, a response was defined by both a relative and an absolute change, with different cut-offs with regard to the drug, the route of administration and the OA localization.
Objective: To propose a simplified set of responder criteria with a similar cut-off, whatever the drug, the route or the OA localization.
Methods: Data driven approach: (1) Two databases were considered: the "elaboration" database with which the formal OARSI sets of responder criteria were elaborated, and the "revisit" database. (2) Six different scenarios were evaluated: The two formal OARSI sets of criteria; Four proposed scenarios of simplified sets of criteria. Data from clinical randomized blinded placebo controlled trials were used to evaluate the performances of the two formal scenarios with two different databases ("elaboration" versus "revisit") and those of the four proposed simplified scenarios within the "revisit" database. The placebo effect, active effect, treatment effect, and the required sample arm size to obtain the placebo effect and the active treatment effect observed were the performances evaluated for each of the six scenarios. Experts' opinion approach: Results were discussed among the participants of the OMERACT VI meeting, who voted to select the definite OMERACT-OARSI set of criteria (one of the six evaluated scenarios).
Results: Data driven approach: Fourteen trials totaling 1886 OA patients and fifteen studies involving 8164 OA patients were evaluated in the "elaboration"and the "revisit" databases respectively. The variability of the performances observed in the "revisit" database when using the different simplified scenarios was similar to that observed between the two databases ("elaboration" versus "revisit") when using the formal scenarios. The treatment effect and the required sample arm size were similar for each set of criteria. Experts' opinion approach: According to the experts, these two previous performances were the most important of an optimal set of responder criteria. They chose the set of criteria considering both pain and function as evaluation domain and requiring an absolute change and a relative change from baseline to define a response, with similar cut-offs whatever the drug, the route of administration or the OA localization.
Conclusion: This data driven and experts' opinion approach is the basis for proposing an optimal simplified set of responder criteria for OA clinical trials. Other studies, using other sets of OA patients, are required in order to further validate this proposed OMERACT-OARSI set of criteria.
Similar articles
-
Outcome variables for osteoarthritis clinical trials: The OMERACT-OARSI set of responder criteria.J Rheumatol. 2003 Jul;30(7):1648-54. J Rheumatol. 2003. PMID: 12858473 Review.
-
Response criteria for clinical trials on osteoarthritis of the knee and hip: a report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials response criteria initiative.Osteoarthritis Cartilage. 2000 Nov;8(6):395-403. doi: 10.1053/joca.2000.0361. Osteoarthritis Cartilage. 2000. PMID: 11069723 Review.
-
The effectiveness of hylan G-F 20 in patients with knee osteoarthritis: an application of two sets of response criteria developed by the OARSI and one set developed by OMERACT-OARSI.Osteoarthritis Cartilage. 2005 Feb;13(2):104-10. doi: 10.1016/j.joca.2004.10.016. Osteoarthritis Cartilage. 2005. PMID: 15694571 Clinical Trial.
-
Patient acceptable symptom state and OMERACT-OARSI set of responder criteria in joint replacement. Identification of cut-off values.Osteoarthritis Cartilage. 2012 Feb;20(2):87-92. doi: 10.1016/j.joca.2011.11.007. Epub 2011 Nov 20. Osteoarthritis Cartilage. 2012. PMID: 22155074
-
Post-Hoc analysis of a head-to-head hyaluronic acid comparison in knee osteoarthritis using the 2004 OMERACT-OARSI responder criteria.Clin Drug Investig. 2008;28(1):37-45. doi: 10.2165/00044011-200828010-00005. Clin Drug Investig. 2008. PMID: 18081359
Cited by
-
High-Dose Neutrophil-Depleted Platelet-Rich Plasma Therapy for Knee Osteoarthritis: A Retrospective Study.J Clin Med. 2024 Aug 15;13(16):4816. doi: 10.3390/jcm13164816. J Clin Med. 2024. PMID: 39200958 Free PMC article.
-
Oral resveratrol in adults with knee osteoarthritis: A randomized placebo-controlled trial (ARTHROL).PLoS Med. 2024 Aug 13;21(8):e1004440. doi: 10.1371/journal.pmed.1004440. eCollection 2024 Aug. PLoS Med. 2024. PMID: 39137167 Free PMC article. Clinical Trial.
-
Endophenotypes of Primary Osteoarthritis of the Hip Joint in the Bulgarian Population over 60 Years Old.Life (Basel). 2024 May 11;14(5):622. doi: 10.3390/life14050622. Life (Basel). 2024. PMID: 38792642 Free PMC article.
-
Krill Oil for Knee Osteoarthritis: A Randomized Clinical Trial.JAMA. 2024 Jun 18;331(23):1997-2006. doi: 10.1001/jama.2024.6063. JAMA. 2024. PMID: 38776073 Clinical Trial.
-
The impact of diabetes status on pain and physical function following total joint arthroplasty for hip and knee osteoarthritis: variation by sex and body mass index.Sci Rep. 2024 May 15;14(1):11152. doi: 10.1038/s41598-024-61847-0. Sci Rep. 2024. PMID: 38750058 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical